LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

38%

62%

103 / 352 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. märts 2026, 23:35 UTC

Uudisväärsed sündmused

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1. märts 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1. märts 2026, 23:19 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1. märts 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1. märts 2026, 22:55 UTC

Uudisväärsed sündmused

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1. märts 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1. märts 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1. märts 2026, 22:38 UTC

Market Talk

Uudisväärsed sündmused

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1. märts 2026, 22:21 UTC

Tulu

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1. märts 2026, 22:17 UTC

Market Talk

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1. märts 2026, 22:00 UTC

Market Talk

Uudisväärsed sündmused

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1. märts 2026, 21:40 UTC

Market Talk

Uudisväärsed sündmused

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1. märts 2026, 21:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1. märts 2026, 21:30 UTC

Market Talk

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1. märts 2026, 21:27 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1. märts 2026, 21:19 UTC

Market Talk

Uudisväärsed sündmused

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1. märts 2026, 20:58 UTC

Market Talk

Uudisväärsed sündmused

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1. märts 2026, 20:40 UTC

Market Talk

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1. märts 2026, 20:24 UTC

Market Talk

Uudisväärsed sündmused

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

103 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.